About 32 results found for searched term "Bromodomain IN-2" (0.1 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41642 | Bromodomain IN-2 | Epigenetic Reader Domain |
| BD-IN-1 is a pan bromodomain (BD) inhibitor with KD values of 250, 420, 130, 430, 67, 240, 970 nM for BRD4(1), CBP, BRPF1B, BRD7, BRD9, BRDT(1), CECR2 respectively. | ||
| M41644 | Bromodomain inhibitor-12 | Epigenetic Reader Domain |
| Bromodomain inhibitor-12 is a bromodomain inhibitor that can be used in the research of autoimmune and inflammatory diseases. | ||
| M2167 | (+)-JQ1 | Epigenetic Reader Domain |
| JQ1 | ||
| (+)-JQ1 is a BET bromodomain inhibitor that acts on BRD4(2) with an IC50 of 33 nM and binds to all bromodomain domains in the BET family, but not to bromodomain domains outside the BET family. JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway, and JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway. | ||
| M2903 | OTX015 (Birabresib) | Epigenetic Reader Domain |
| MK-8628; Birabresib | ||
| OTX015 is a potent BET bromodomain inhibitor with EC50 ranging from 10 to 19 nM for BRD2, BRD3, and BRD4. | ||
| M2932 | PFI-1 | Epigenetic Reader Domain |
| PFI-1 is a selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC50 of 0.22 μM. | ||
| M25394 | BPTF-IN-1 | Epigenetic Reader Domain |
| compound AU1 | ||
| BPTF-IN-1 (compound AU1) is a selective bromodomain and PHD finger containing transcription factor (BPTF) bromodomain inhibitor with a Kd of 2.8 μM. BPTF-IN-1 shows to be selective for BPTF over BRD4 bromodomain. | ||
| M4909 | GSK2801 | Epigenetic Reader Domain |
| GSK2801 is a selective bromodomains BAZ2A/B inhibitor with KD of 257 nM and 136 nM, respectively. | ||
| M5064 | PFI-4 | Epigenetic Reader Domain |
| PFI-4 is a potent and selective BRPF1 bromodomain inhibitor with IC50 of 80 nM. PFI-4 (1.25 µM; 7 or 11 days) inhibits differentiation of human osteoclasts. | ||
| M5258 | Mivebresib | Epigenetic Reader Domain |
| ABBV-075 | ||
| Mivebresib(ABBV-075) is a novel BET family bromodomain inhibitor. It binds bromodomains of BRD2/4/T with similar affinities (Ki of 1-2.2 nM) and highly selective for 18 bromodomain proteins tested (Kd > 1 μM; more than 600-fold selectivity vs. BRD4) | ||
| M8467 | OF-1 | Others |
| OF-1 is a chemical probe for the bromodomains of the BRPF (BRomodomain and PHD Finger containing) family of scaffolding proteins (BRPF1, BRPF2, BRPF3) that assemble histone acetyltransferase (HAT) complexes of the MYST family members MOZ and MORF. | ||
| M8672 | CeMMEC13 | DNA/RNA Synthesis |
| CeMMEC13 is a potent inhibitor of the second bromodomain of the transcription initiation factor TAF1 with an an IC50 value of 2. | ||
| M9144 | PFI-3 | Epigenetic Reader Domain |
| PFI-3 is a selective chemical probe for SMARCA bromodomains, including SMARCA2, SMARCA4 and PB1(5) bromodomains with a Kd of 89 nM. | ||
| M10822 | GNE-781 | Epigenetic Reader Domain |
| GNE-781 (compound 19) is a highly potent, orally active, selective bromodomain inhibitor against cyclic adenosine monophosphate response element binding protein (CBP). The IC50 value is 0.94 nM (in TR-FRET assay). GNE-781 also suppresses BRET and BRD4(1), with IC50s of 6.2 nM and 5100 nM, respectively. GNE-781 has antitumor activity. | ||
| M10862 | MS645 | Epigenetic Reader Domain |
| MS645 is a BET bromodomains (BrD) inhibitor for K of BRD4-BD1/BD2i The value is 18.4 nM. MS645 spatially limits the divalent inhibition of BRD4 BrDs, resulting in sustained inhibition of BRD4 transcriptional activity in solid tumor cells. | ||
| M13823 | L-Moses | Epigenetic Reader Domain |
| L-45 | ||
| L-Moses (L-45) is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a Kd of 126 nM. | ||
| M13824 | L-Moses dihydrochloride | Epigenetic Reader Domain |
| L-45 dihydrochloride | ||
| L-Moses (L-45) dihydrochloride is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a Kd of 126 nM. | ||
| M13825 | Molibresib besylate | Epigenetic Reader Domain |
| GSK 525762C; I-BET 762 besylate | ||
| Molibresib besylate (GSK 525762C; I-BET 762 besylate) is a BET bromodomain inhibitor with IC50 of 32.5-42.5 nM. | ||
| M13826 | TPOP146 | Epigenetic Reader Domain |
| TPOP146 is a selective CBP/P300 benzoxazepine bromodomain inhibitor with Kd values of 134 nM and 5.02 μM for CBP and BRD4. | ||
| M20549 | GSK 5959 | Epigenetic Reader Domain |
| GSK5959 is a potent and selective BRPF1 bromodomain inhibitor with an IC50 of 80 nM and exhibits >100-fold selectivity for BRPF1 over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains. | ||
| M20613 | PF-CBP1 HCl | Epigenetic Reader Domain |
| PF-CBP1 HCl is a highly selective inhibitor of the bromodomain of CREB-binding protein(CREBBP).It inhibits CREBBP and p300 bromodomains with IC50 of 125 and 363 nM respectively. | ||
| M25395 | GSK1379725A | Epigenetic Reader Domain |
| AU1; AU-1 | ||
| GSK1379725A (AU1) is the first selective BPTF (Bromodomain PHD Finger Transcription Factor) ligand with a Kd of 2.8 uM, showing no binding activity for Brd4. | ||
| M25513 | GNE-207 | Epigenetic Reader Domain |
| GNE-207 is a potent, selective and orally bioavailable inhibitor of the bromodomain of CBP, with an IC50 of 1 nM, exhibits a selectively index of >2500-fold against BRD4(1). GNE-207 shows excellent CBP potency, with an EC50 of 18 nM for MYC expression in MV-4-11 cells. | ||
| M25523 | Y08284 | Epigenetic Reader Domain |
| Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Y08284 has antitumor activity. | ||
| M27706 | RVX-297 | Epigenetic Reader Domain |
| RVX-297 is a potent, orally active BET bromodomain inhibitor with selectivity for BD2. RVX-297 shows IC50s of 0.08, 0.05, and 0.02 μM for BRD2(BD2), BRD3(BD2), and BRD4(BD2), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types. RVX-297 is effective in acute inflammation and autoimmunity models. | ||
| M28391 | I-BET282 | Epigenetic Reader Domain |
| I-BET282 is a pan-inhibitor of all eight BET bromodomains, and selectivity over other representative bromodomain-containing proteins. I-BET282 shows pIC50s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD). | ||
| M28718 | CD161 | Epigenetic Reader Domain |
| NKR-P1A | ||
| CD161 (NKR-P1A) is a potent, selective and orally bioavailable bromodomain and extra-terminal (BET) bromodomain inhibitor with an IC50s of 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2, respectively. CD161 has good anticancer activity. | ||
| M28741 | GS-626510 | Epigenetic Reader Domain |
| GS-626510 is a potent, and orally active BET family bromodomains inhibitor, with Kd values of 0.59-3.2 nM for BRD2/3/4, with IC50 values of 83 nM and 78 nM foe BD1 and BD2, respectively. | ||
| M28788 | BAZ2-ICR | Epigenetic Reader Domain |
| BAZ2-ICR is a potent, selective, cell active and orally active BAZ2A/B bromodomains inhibitor with IC50s of 130 nM and 180 nM, and Kds of 109 nM and 170 nM, respectively. BAZ2-ICR shows 10-15-fold selectivity for binding BAZ2A/B over CECR2 and >100-fold selectivity over all other bromodomains. BAZ2-ICR is an epigenetic chemical probe. | ||
| M28814 | GSK8573 | Epigenetic Reader Domain |
| GSK8573 is an inactive control compound for GSK2801 (acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains). GSK8573 has binding activity to BRD9 with a Kd value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain familiy. GSK8573 can be used as a structurally related negative control compound in biological experiments. | ||
| M28986 | NI-57 | Epigenetic Reader Domain |
| NI-57 is an inhibitor of bromodomain and plant homeodomain finger-containing (BRPF) famlily of proteins, with IC50s of 3.1, 46 and 140 nM for BRPF1, BRPF2 (BRD1) and BRPF3, respectively. | ||
| M29026 | GNE-371 | DNA/RNA Synthesis |
| GNE-371 is a potent and selective chemical probe for the second bromodomains of human transcription-initiation-factor TFIID subunit 1 and transcription-initiation-factor TFIID subunit 1-like, with an IC50 of 10 nM for TAF1(2). | ||
| M29089 | GSK8814 | Epigenetic Reader Domain |
| GSK8814 is a potent, selective, and ATAD2/2B bromodomain chemical probe and inhibitor, with a binding constant pKd=8.1 and a pKi=8.9 in BROMOscan. GSK8814 binds to ATAD2 and BRD4 BD1 with pIC50s of 7.3 and 4.6, respectively. GSK8814 shows 500-fold selectivity for ATAD2 over BRD4 BD1. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
